The worldwide magnitude of the COVID-19 pandemic is ineffable;
it is unsurprisingly compared to the Spanish flu pandemic, which ravaged the
world during the First World War (adding fuel to the fire!). One of the pandemic's
various positive impacts has been the unprecedented research collaboration and
data sharing across the world. Such singular efforts made it possible to cut
down the usual time to achieve an approved vaccine from 10+ years to
less than a year.
To put things into perspective, it took 60 years from the
time of the first polio outbreak to developing its vaccine; in the case of
Ebola, it took 15 years. Vaccine candidates for SARS-CoV-1 and MERS did not receive
the necessary impetus to advance into fruition. However, with SARS-CoV-2, the
situation is very different. Global initiatives such as ACTIV (Accelerating
COVID-19 Therapeutic Interventions and Vaccines), a public-private partnership
comprising of bigwigs like CDC, FDA, EMA (European Medicines Agency), and
numerous leading biopharmaceutical enterprises. Another project on a similar
scale is Operation Warp Speed, which has invited comparison to the infamous
Manhattan Project.
What is an "ideal" COVID-19 vaccine? There are
three criteria from the immunological perspective: 1) It induces a robust humoral
immune response that produces long-lasting neutralizing antibodies against
SARS-CoV-2 antigens, 2) It generates a strong cell-mediated immunity that
includes the production of memory T cells, 3) It should be free of any serious
local or systemic adverse effects. Considering the logistics of vaccinating the entire world, there are three more criteria: 1) It should be easy to administer,
preferably in one or two doses, 2) It should be easy to produce on a
large-scale, 3) Its storage should be uncomplicated, ideally possible at room
temperature.
Source: Front.
Pharmacol., 19 June 2020 | https://doi.org/10.3389/fphar.2020.00937
Let us discuss the vaccines that are currently in
development. We all have heard about a few of them in the news and social media,
namely, Pfizer, Moderna, Covaxin, Astra Zeneca, and so on. There are,
impressively, 125+ SARS-CoV-2 vaccines in development globally. Broadly,
there are six platforms currently being utilized for vaccine development –
1. DNA
2. mRNA (examples – Moderna, Pfizer)
3. Protein (Subunit vaccines)
4. Viral vector – replicating/non-replicating
(examples - Oxford/Astra Zeneca, Johnson & Johnson)
5. Live attenuated virus
6. Inactivated virus
Almost all of the above models have targeted the spike glycoprotein,
which is present on the surface of SARS-CoV-2, to interfere with the viral
entry into a cell.
This article is an oversimplified summary of the vaccine
development process. I haven't covered the vaccine platforms, molecular
targets, and vaccine candidates in detail. With the advent of vaccine administration,
whether it's Pfizer's or any other, there will be a massive surge in
vaccine-related information. There will be challenges at every step, from
distribution to underdeveloped areas of the world to alleviate the concerns
of the skeptical anti-vaxxers. Let us hope that these vaccines start the end of
the pandemic.
-Vinayak